EU Pricing Pressures On Generics And Biosimilars Risk Killing Industry –EGA Execs
New EGA president and director general say Europe must end downward pricing pressures on generic medicines manufacturers or risk losing that industry altogether.
You may also be interested in...
Can European Efficiency Measures Boost Generics And Biosimilars? – An Interview With EGA’s Adrian van den Hoven
EGA Director General Adrian van den Hoven will call on the new European Commission and Parliament to introduce efficiency policies to increase the uptake of and access to generic drugs and biosimilars.
Official negotiations between the U.S. and EU on the Transatlantic Trade and Investment Partnership trade agreement began last week. Medical device industry associations representing both regions want the harmonization of U.S. and EU device industry regulations to be part of the agreement.
Greece has slashed its pharmaceutical budget in half by price cuts and withholding payments, but it is now turning to generics to fulfill its citizens’ health care needs.